+44 20 8123 2220
info@marketpublishers.com

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

https://marketpublishers.com/r/MB07AC7B4ABEN.html
Date: June 2017
Pages: 260
Price: US$ 2,520.00 (Single User License)
ID: MB07AC7B4ABEN

Abstracts

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

For a long time, messenger RNA (mRNA) was thought to be a poor choice for a therapeutic agent given its relatively short half-life and its immunogenicity. But mRNA is rather versatile and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Range of clinical mRNA applications

Cancer Vaccines

Infectious Disease Vaccines

In vivo Therapeutics

Gene Editing

Standardized preselected

Individualized shared antigens

+44 20 8123 2220
info@marketpublishers.com

Individualized neoantigens

Prophylactic vaccines

Therapeutic vaccines

Synthetic self-amplifying mRNA vaccines for pandemic outbreaks

Therapeutic proteins

Therapeutic antibodies

Ex vivo gene editing of gene defects

In vivo gene editing of gene defects

Ex vivo gene editing of autologous and allogeneic T-cells

mRNA Technologies have attracted more than US$ 3.4 bln in equity financing and frontloaded partnership payments. Further billions of US$ have been committed to mRNA R&D funding and potential milestone payments. A select group of major pharmaceutical and rare disease specialist biopharmaceutical companies have partnered with mRNA technology companies. At least 16 mRNA vaccines and therapeutics are in clinical stages and a considerable number is in IND or pre-IND stage.

This report mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals as of June 2017 brings you up-to-date regarding key mRNA players, key mRNA technologies and applications, mRNA vaccines & therapeutics, business projects, business deals and funding opportunities. The report analyzes the mRNA vaccine and therapeutic pipelines and stakeholders in the field, especially technology companies and rare disease biopharma and major pharmaceutical companies. The report highlights the value of mRNA vaccines and therapeutics in terms of partnering economic condition and equity financing rounds.

What will you find in the report?

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

4 PIPELINE ANALYSIS

5 PROFILES OF SELECTED MRNA & DELIVERY TECHNOLOGIES

6 TECHNOLOGY ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

7 COMPANY PROFILES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Product link: https://marketpublishers.com/r/MB07AC7B4ABEN.html

Price: US$ 2,520.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/MB07AC7B4ABEN.html